SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Howard Hoffman who wrote (1367)11/25/1997 12:52:00 PM
From: Roudy  Read Replies (1) | Respond to of 1762
 
In the past, I have found Coulter to be aggressive on their reports of Brexxar, where as, IDEC has been more consevative and factual on their reporting of Rituxan. IMO, Don.



To: Howard Hoffman who wrote (1367)11/25/1997 10:29:00 PM
From: Bob L  Read Replies (1) | Respond to of 1762
 
The clinical trials seem to indicate Bexxar is significantly more effective than Rituximab when used alone. However, Rituximab when combined with chemotherapy looks promising. Its anybody's guess which will be best for an individual patient or patients.

A couple of summary articles
pslgroup.com
ama-assn.org

Not the best articles, but what I happen to have around.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News